Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
warfarin sodium, Quantity: 1 mg
Viatris Pty Ltd
Tablet, uncoated
Excipient Ingredients: stearic acid; magnesium stearate; maize starch; lactose; quinoline yellow aluminium lake; amaranth aluminium lake
Oral
500 tablets (hospital only), 50 tablets
(S4) Prescription Only Medicine
COUMADIN is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. COUMADIN is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. COUMADIN is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (TIA, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. COUMADIN is indicated for use as an adjunct in the treatment of coronary occlusion.
Visual Identification: Light tan coloured tablet, scored, embossed COUMADIN above break bar and "1" below.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius; Container Closure: Child resistant closure
Registered
1992-10-13
COUMADIN ® C O U M A D I N CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. WHY AM I USING COUMADIN? COUMADIN contains the active ingredient warfarin. COUMADIN is used to prevent blood from excessive clotting or forming harmful clots. For more information, see Section 1. Why am I using COUMADIN? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I USE COUMADIN? Do not use if you have ever had an allergic reaction to COUMADIN or any of the ingredients listed at the end of the CMI. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING. For more information, see Section 2. What should I know before I use COUMADIN? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with COUMADIN and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I USE COUMADIN? • Follow your doctor’s directions exactly about how much COUMADIN to take. Different people require different amounts of this medicine, and the dosage is adjusted to suit you. Your doctor will determine how much to take through blood tests. • COUMADIN should be taken at about the same time each day. More instructions can be found in Section 4. How do I use COUMADIN? in the full CMI. 5. WHAT SHOULD I KNOW WHILE USING COUMADIN? THINGS YOU SHOULD DO • Remind any doctor, dentist or pharmacist you visit that you are using COUMADIN. • If you are going to have surgery, tell the surgeon or anaesthetist that you are taking this medicine. • If you become pregnant while taking this medicine, tell your doctor immediately. • If you are about to have any blood tests, tell your doctor that you are taking this medicine. THINGS YOU SHOULD NOT DO • Do not stop taking your medicine or lower the dosage without checking with your doctor. • There ar Read the complete document
AUSTRALIAN PRODUCT INFORMATION COUMADIN ® _warfarin sodium _ 1 NAME OF THE MEDICINE Warfarin sodium 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each COUMADIN tablet contains 1 mg, 2 mg or 5 mg of warfarin sodium as the active ingredient. Excipients of known effect: sugars as lactose and sulfites. For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS. 3 PHARMACEUTICAL FORM COUMADIN 1 mg tablets are light tan coloured, scored, embossed COUMADIN above break bar and “1” below. COUMADIN 2 mg tablets are lavender coloured, scored, embossed COUMADIN above break bar and “2” below. COUMADIN 5 mg tablets are green coloured, scored, embossed COUMADIN above break bar and “5” below. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS COUMADIN is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. COUMADIN is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. COUMADIN is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (e.g. previous thromboembolism (TIA, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. COUMADIN is indicated for use as an adjunct in the treatment of coronary occlusion. 4.2 DOSE AND METHOD OF ADMINISTRATION It cannot be emphasised too strongly that treatment of each patient is a highly individualised matter. COUMADIN, a narrow therapeutic range (index) drug, may be affected by factors such as other drugs, dietary Vitamin K and genetic variations in CYP2CP and VKORC1 enzymes. Dosage should be controlled by periodic determinations of International Normalised Ratio (INR) or other suitable coagulation tests and the condition being treated (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION - Administration) The following ranges of INR may be considered for the following listed conditions or procedures; however prescribers should consult local clinical guidelines for curren Read the complete document